Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care
Hear expert insights on when to use interleukin inhibitors in the course of psoriatic arthritis.
This program is intended for rheumatology specialists including physicians and other healthcare providers who care for patients with psoriasis.
Upon completion of this activity, participants should be able to:
- Summarize the accumulating clinical study and real-world evidence regarding the efficacy and safety of IL-targeted biologics in patients with PsA who have had an inadequate response to conventional synthetic DMARDs
- Describe the clinical results from recent studies that evaluated an interleukin blocker as initial therapy in patients with a new diagnosis of moderate to severe PsA
Vinod Chandran, MBBS, MD, DM, PhD
Division of Rheumatology
Department of Medicine
University of Toronto
University Health Network
Vinod Chandran, MBBS, MD, DM, PhD, has disclosed that he has received funds for research support from AbbVie and Amgen and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB.
Alexis Ogdie, MD, MSCE
Associate Professor of Medicine and Epidemiology
Perelman School of Medicine
University of Pennsylvania
Alexis Ogdie, MD, MSCE, has disclosed that she has received funds for research support from Amgen; consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Janssen, Gilead Sciences, Lilly, Novartis, and Pfizer; and other financial or material support from Novartis and Pfizer.
Zachary Schwartz, MSc
Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report
Carolyn Skowronski, PharmD
Associate Director, Scientific Services
Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report
Megan Cartwright, PhD
Senior Clinical Editor
Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Provided by Clinical Care Options, LLC.
Physician Continuing Medical Education
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 AMA PRA Category 1 Credit™
This course is offered through MyCME.
To take this course you will be redirected to MyCME's website. You must login or create an account with MyCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!